218 related articles for article (PubMed ID: 11443170)
1. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.
Suzuki T; Nakamura Y; Kato H
Nutrients; 2018 Feb; 10(3):. PubMed ID: 29495518
[TBL] [Abstract][Full Text] [Related]
3. Predictors of bone mineral density in patients receiving glucocorticoid replacement for Addison's disease.
Furman K; Gut P; Sowińska A; Ruchała M; Fichna M
Endocrine; 2024 May; 84(2):711-719. PubMed ID: 38334892
[TBL] [Abstract][Full Text] [Related]
4. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
Iseri K; Iyoda M; Watanabe M; Matsumoto K; Sanada D; Inoue T; Tachibana S; Shibata T
PLoS One; 2018; 13(3):e0193846. PubMed ID: 29543887
[TBL] [Abstract][Full Text] [Related]
5. The Long-Term Effects of Growth Hormone Replacement on Bone Mineral Density and Trabecular Bone Score: Results of the 10-Year Prospective Follow-up.
Vaňuga P; Kužma M; Stojkovičová D; Smaha J; Jackuliak P; Killinger Z; Payer J
Physiol Res; 2021 Nov; 70(Suppl 1):S61-S68. PubMed ID: 35503051
[TBL] [Abstract][Full Text] [Related]
6. Study on the Effect of Bushen Zhuanggu Tablet Combined with Conventional Regimen on Bone Mineral Density Improvement, Functional Recovery and Fracture Risk Prevention in Patients with Postmenopausal Osteoporosis.
Chen T; Li G; Xu Y
Comput Math Methods Med; 2023; 2023():4846392. PubMed ID: 37455682
[TBL] [Abstract][Full Text] [Related]
7. Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids.
Sawamura M; Komatsuda A; Togashi M; Wakui H; Takahashi N
Intern Med; 2017; 56(6):631-636. PubMed ID: 28321061
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis.
Unal E; Abaci A; Bober E; Büyükgebiz A
J Pediatr Endocrinol Metab; 2006 Apr; 19(4):523-8. PubMed ID: 16759038
[TBL] [Abstract][Full Text] [Related]
9. Alendronate and raloxifene therapy in the early period after hip fracture.
Ohishi T; Ichikawa T; Ito T; Koyama H; Miyagi M; Hoshino H; Takahashi M
J Rural Med; 2011; 6(1):16-21. PubMed ID: 25650026
[TBL] [Abstract][Full Text] [Related]
10. Bone resorption and fracture across the menopausal transition: the Study of Women's Health Across the Nation.
Cauley JA; Danielson ME; Greendale GA; Finkelstein JS; Chang YF; Lo JC; Crandall CJ; Neer RM; Ruppert K; Meyn L; Prairie BA; Sowers MR
Menopause; 2012 Nov; 19(11):1200-7. PubMed ID: 22850443
[TBL] [Abstract][Full Text] [Related]
11. Uses and limitations of bone mineral density measurements in the management of osteoporosis.
Small RE
MedGenMed; 2005 May; 7(2):3. PubMed ID: 16369382
[TBL] [Abstract][Full Text] [Related]
12. Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study.
Villagómez Vega A; Gámez Nava JI; Ruiz González F; Pérez Romero M; Trujillo Rangel WÁ; Nuño Arana I
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833451
[TBL] [Abstract][Full Text] [Related]
13. Low bone mineral density in a growth hormone deficient (GHD) adolescent.
Capozzi A; Casa SD; Altieri B; Pontecorvi A
Clin Cases Miner Bone Metab; 2013 Sep; 10(3):203-5. PubMed ID: 24554933
[TBL] [Abstract][Full Text] [Related]
14. Seven years' experience with alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Ther Clin Risk Manag; 2010 Apr; 6():201-6. PubMed ID: 20463781
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Osteogenic Exercise Efficacy via Bone Turnover Markers in Premenopausal Women: A Randomized Controlled Trial.
Sanchez-Trigo H; Kemmler W; Duque G; Sañudo B
Int J Sport Nutr Exerc Metab; 2024 Jan; 34(1):20-29. PubMed ID: 37917954
[TBL] [Abstract][Full Text] [Related]
16. Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial.
Lomax AJ; Yee Yap S; White K; Beith J; Abdi E; Broad A; Sewak S; Lee C; Sambrook P; Pocock N; Henry MJ; Yeow EG; Bell R
J Bone Oncol; 2013 Dec; 2(4):145-53. PubMed ID: 26909285
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Generic Alendronate for Osteoporosis Treatment.
Jarusriwanna A; Malisorn S; Tananoo S; Areewong K; Rasamimongkol S; Laoruengthana A
Orthop Res Rev; 2024; 16():85-91. PubMed ID: 38410814
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with osteoporosis and fractures in patients with systemic lupus erythematosus: Kyoto Lupus Cohort.
Nakajima T; Doi H; Watanabe R; Murata K; Takase Y; Inaba R; Itaya T; Iwasaki T; Shirakashi M; Tsuji H; Kitagori K; Akizuki S; Nakashima R; Onishi A; Yoshifuji H; Tanaka M; Ito H; Hashimoto M; Ohmura K; Morinobu A
Mod Rheumatol; 2023 Dec; 34(1):113-121. PubMed ID: 36680424
[TBL] [Abstract][Full Text] [Related]
19. Impact of GH replacement therapy on sleep in adult patients with GH deficiency of pituitary origin.
Morselli LL; Nedeltcheva A; Leproult R; Spiegel K; Martino E; Legros JJ; Weiss RE; Mockel J; Van Cauter E; Copinschi G
Eur J Endocrinol; 2013 May; 168(5):763-70. PubMed ID: 23447518
[TBL] [Abstract][Full Text] [Related]
20. Bone quality in zebrafish vertebrae improves after alendronate administration in a glucocorticoid-induced osteoporosis model.
Bohns FR; Akhtar R; Chuang YJ; Chen PY
J Mech Behav Biomed Mater; 2024 Jun; 154():106521. PubMed ID: 38555661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
